Clinical Trial Update: A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant nivolumab plus relatlimab vs nivolumab alone after complete resection of stage III-IV melanoma was terminated, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: TERMINATED | Results posted: 2026-01-08